Clinical Study for AL-CM

Clinical Study Protocol for the Treatment of Immunoglobulin Light Chain Amyloidosis Cardiomyopathy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04924998

Enrollment

400

Registered

2021-06-14

Start date

2021-06-01

Completion date

2031-06-01

Last updated

2023-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunoglobulin Light Amyloidosis Cardiomyopathy

Brief summary

In this study, patients diagnosed with Al-CM were selected to observe the effect of treatment and conduct long-term follow-up.

Interventions

DRUGcurrent treatment of AL-CM

current treatment of AL-CM

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients aged 18-90 years, regardless of gender, diagnosed with Al-CM at the Second Affiliated Hospital of Zhejiang University School of Medicine; * Patients have the ability to understand the test, can cooperate with investigators.

Exclusion criteria

* Unable to understand or unwilling to fill in informed consent forms or follow visitors

Design outcomes

Primary

Measure	Time frame	Description
Primary Outcome	10 year	incidences of MACE-4(cardiovascular death, myocardial infarction, stroke and hospitalized unstable angina)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026